Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2021-06-30
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Electronic Cigarettes as a Harm Reduction Strategy Among Patients With COPD
NCT04465318
Supporting Smoke-Free Policy Compliance in Public Housing
NCT05016505
Effects of Intensive Behavioral Training Program on Impulsivity and Inhibitory Control in Smokers
NCT01314378
Harm Reduction for Smokers With Mental Illness
NCT06543407
Engaging Working Memory and Distress Tolerance to Aid Smoking Cessation
NCT03565497
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Smoke Cessation Group
Mindfulness-based smoking cessation sessions will follow the mindfulness based addiction treatment (MBAT) intervention for smoking cessation. Sessions are in group format for two hours, weekly. Two groups of sessions with about 10 participants per group will be organized.
Mindfulness Based addition treatment
The intervention is comprised of 8 weekly group MBAT sessions. Two weekly groups of about 10 participants each will be conducted. All participants will also have the option to receive nicotine patches, gum, or lozenges for four weeks as part of their time in the study. Participants will complete surveys at enrollment (baseline), immediately after their last MBAT session (around 2 months after enrollment) and one month after completing treatment (3 months post-enrollment). Surveys will assess primary and secondary outcomes and satisfaction with the intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mindfulness Based addition treatment
The intervention is comprised of 8 weekly group MBAT sessions. Two weekly groups of about 10 participants each will be conducted. All participants will also have the option to receive nicotine patches, gum, or lozenges for four weeks as part of their time in the study. Participants will complete surveys at enrollment (baseline), immediately after their last MBAT session (around 2 months after enrollment) and one month after completing treatment (3 months post-enrollment). Surveys will assess primary and secondary outcomes and satisfaction with the intervention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current smoker (\>= 5 cigarettes per day). Dual tobacco users are eligible as long as their primary tobacco product is cigarettes.
* Ready to quit smoking cigarettes within 30 days
* Able to attend the 8 weekly MBAT sessions at the scheduled days/times
* NYCHA resident
* English language
* Able to provide informed consent
Exclusion Criteria
* Patient Health Questionnaire-2 (PHQ-2) score indicating current risk for depression
* Self-reported diagnosis of schizophrenia, bipolar disorder, schizotypal disorder or other psychotic disorder
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NYU Langone Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erin Rogers
Role: PRINCIPAL_INVESTIGATOR
NYU Langone Health
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-01435
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.